This is the service for the supervision of oral chemotherapy treatment for malignant disease where the agent(s) has a significant risk of toxicity in the period immediately following initiation. The physician must be available to intervene in a timely fashion for a 24 hour period following the initiation of the treatment. In addition to the Common Elements in this Schedule, this service includes the provision of the following services to the same patient: a. evaluation of any relevant laboratory, diagnostic and/or imaging investigations; and b. all discussion or advice, whether by telephone or otherwise, involving the patient, staff, patient’s relative(s) or patient’s representative related to the oral chemotharapy for a period of twenty-one (21) days following initiation of the agent(s).
1. G388 is not eligible for payment for the same patient in the same month where G382 is payable.
2. G388 is only eligible for payment once every twenty-one (21) days to a maximum of six (6) services per patient per 12 month period.
Examples of special oral chemotherapy include fludarabine, imatinib, dasatanib, nilotinib, erlotinib, capecitabine, sunitinib, sorafenib, thalidomide, temazolamide and lenalidomide.